Continuing, the relationship between the presence of circulating tumor DNA and plasma levels of kinase inhibitors in patients with advanced BRAF(V600) mutant melanoma is being investigated in a study entitled “Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma” (Table 2). Here, BRAF is linked to melanoma.